Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
Boehringer Ingelheim
Eli Lilly and Company
Tomsk National Research Medical Center of the Russian Academy of Sciences
Incyte Corporation
Daiichi Sankyo
AstraZeneca
Pfizer
Genentech, Inc.
University of Oklahoma
USWM, LLC (dba US WorldMeds)
Werewolf Therapeutics, Inc.
National Cancer Institute (NCI)
City of Hope Medical Center
AbbVie
NovoCure Ltd.
Hoosier Cancer Research Network
AstraZeneca
Deciphera Pharmaceuticals, LLC
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Turning Point Therapeutics, Inc.
Ohio State University Comprehensive Cancer Center
Immuneering Corporation
BeiGene
Daiichi Sankyo
Hummingbird Bioscience
National Cancer Institute (NCI)
Mirati Therapeutics Inc.
Carisma Therapeutics Inc
NextCure, Inc.
Bristol-Myers Squibb
Actuate Therapeutics Inc.
Revolution Medicines, Inc.
Salubris Biotherapeutics Inc
NeoImmuneTech
Adaptimmune